NA
PRME icon

NewEdge Advisors’s Prime Medicine PRME Stock Holding History

NewEdge Advisors’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.48K Hold
1,000
– – ﹤0.01% 3681
2025
Q4 		$3.47K Hold
1,000
– – ﹤0.01% 3770
2025
Q3 		$5.54K Buy
+1,000
New +$4.06K ﹤0.01% 3501

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NewEdge Advisors's PRME Position: Q1 2026 in Review

NewEdge Advisors held its Prime Medicine (PRME) position steady in Q1 2026 at 1,000 shares worth $3.48K. The position accounts for ﹤0.01% of the portfolio, ranked #3681.

NewEdge Advisors first reported a position in PRME in Q3 2025 and has held it in 3 quarters since. The position peaked at $5.54K in Q3 2025. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • NewEdge Advisors held 1,000 shares of Prime Medicine worth $3.48K as of Q1 2026.
  • NewEdge Advisors left its Prime Medicine share count unchanged in Q1 2026.
  • Prime Medicine made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #3681 holding.
  • NewEdge Advisors first reported a position in Prime Medicine in Q3 2025 and has held it in 3 quarters since.
  • NewEdge Advisors's Prime Medicine position peaked at $5.54K in Q3 2025.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.